Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$42.25+0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HRMY
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $42 HRMY trades at 11× p/e, below its 22× p/e peer median. Our $94 fair value sits well above the price. We hold it with low confidence: our number sits well above the analyst range and the peer anchor overstates how cheap it looks. Analysts target $34–$70. Note: our $94 fair value sits above the entire analyst range ($34–$70). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $39.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $274.52 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $315.39 | — | — | Hist. CAGR | high |
| graham number | 12M | $37.73 | — | — | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$34.00 – $70.00 (median $39.00) · 7 analysts · as of 2026-08-26
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $130.38 |
| 21.6 |
| 6.04 |
| TTM |
| high |
| Peer P/E | 12M | $75.53 | 18.1 | 4.17 | ntm analyst | high |
| Peer P/S | 12M | $185.95 | 11.4 | 16.34 | TTM | high |
| PEG | 12M | $38.27 | 10.3 | 3.72 | TTM | high |
| residual income | 12M | $26.48 | — | — | TTM | high |
| Own P/E history | 12M | $40.81 | 11.0 | 3.72 | TTM | high |
| triangulated | 12M | $87.07 | 22.0 | 3.96 | Triangulated | high |
| Peer P/FCF | 3Y | $198.29 | 21.6 | 9.19 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $105.88 | 18.1 | 5.84 | Analyst | medium |
| Peer P/S | 3Y | $250.12 | 11.4 | 21.97 | guidance | medium |
| PEG | 3Y | $60.13 | 10.3 | 5.84 | Analyst | medium |
| Own P/E history | 3Y | $64.12 | 11.0 | 5.84 | Analyst | medium |
| Peer P/FCF | 5Y | $262.24 | 21.6 | 12.15 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $119.55 | 18.1 | 6.60 | Analyst | medium |
| Peer P/S | 5Y | $282.42 | 11.4 | 24.81 | guidance | medium |
| PEG | 5Y | $67.89 | 10.3 | 6.60 | Analyst | medium |
| Own P/E history | 5Y | $72.40 | 11.0 | 6.60 | Analyst | medium |